Neumora Therapeutics (NMRA) Interest Expenses (2022 - 2026)

Neumora Therapeutics' Interest Expenses history runs 5 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• On a quarterly basis, Interest Expenses changed N/A year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $3.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $330.2 million, up 24.89% from the prior year.
• Interest Expenses fell to $1.9 million in Q1 2026 per NMRA's latest filing, from $2.0 million in the prior quarter.
• Across five years, Interest Expenses topped out at $147.0 million in Q4 2023 and bottomed at $1.0 million in Q3 2025.
• The 5-year median for Interest Expenses is $58.3 million (2024), against an average of $61.6 million.
• Across the five-year window, Interest Expenses increased 3.82% in 2023 and sank 98.63% in 2025, its largest moves.
• Year by year, Interest Expenses stood at $141.6 million in 2022, then gained by 3.82% to $147.0 million in 2023, then slumped by 50.36% to $73.0 million in 2024, then slumped by 97.21% to $2.0 million in 2025, then retreated by 8.94% to $1.9 million in 2026.
• Per Business Quant, the three latest NMRA Interest Expenses figures stand at $1.9 million (Q1 2026), $2.0 million (Q4 2025), and $1.0 million (Q3 2025).